Tocilizumab for KSHV-Associated Multicentric Castleman Disease

Summary

Tocilizumab for KSHV-Associated Multicentric Castleman Disease is a clinical trial^[1].

Key Facts

• Tocilizumab for KSHV-Associated Multicentric Castleman Disease is in the country of United States^[2].
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease's instance of is recorded as clinical trial^[3].
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease's start time is recorded as +2011-09-13T00:00:00Z^[4].
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease's end time is recorded as +2020-07-01T00:00:00Z^[5].
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease's sponsor is recorded as National Cancer Institute^[6].
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease's main subject is recorded as tocilizumab^[7].
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease's main subject is recorded as hyperplasia^[8].
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease's number of participants is recorded as {'unit': '1', 'amount': '+17'}^[9].
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease's title is recorded as Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease^[10].
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[11].
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease's ClinicalTrials.gov ID is recorded as NCT01441063^[12].
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+99'}^[13].
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease's research intervention is recorded as zidovudine^[14].
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease's research intervention is recorded as valganciclovir^[15].
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease's clinical trial phase is recorded as phase II clinical trial^[16].
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease's research site is recorded as United States National Institutes of Health^[17].
• Tocilizumab for KSHV-Associated Multicentric Castleman Disease's study type is recorded as interventional study^[18].